As blockbuster drugs approach patent expiration, life sciences companies face significant revenue risk. Strategic patent portfolio management, validity analysis, and innovation planning can help organizations protect value and maintain competitive advantage beyond loss of exclusivity.

Early-stage IP decisions in life sciences often occur under pressure but carry long-term implications for licensing, valuation, and portfolio flexibility. This article explores how early patent strategy shapes commercialization outcomes.